{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:58:22Z","timestamp":1789919902618,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T00:00:00Z","timestamp":1470614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T00:00:00Z","timestamp":1470614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic HBV (CHB) infected patients with intermediate necroinflammation and fibrosis are recommended to receive antiviral treatment. However, other than liver biopsy, there is a lack of sensitive and specific objective method to determine the necroinflammation and fibrosis stages in CHB patients. This study aims to identify unique serum metabolomic profile associated with histological progression in CHB patients and to develop novel metabolite biomarker panels for early CHB detection and stratification. A comprehensive metabolomic profiling method was established to compare serum samples collected from health donor (n\u2009=\u200967), patients with mild (G\u2009&lt;\u20092 and S\u2009&lt;\u20092, CHB1, n\u2009=\u200952) or intermediate (G\u2009\u2265\u20092 or S\u2009\u2265\u20092, CHB2, n\u2009=\u200936) necroinflammation and fibrosis. Multivariate models were developed to differentiate CHB1 and CHB2 from controls. A set of CHB-associated biomarkers was identified, including lysophosphatidylcholines, phosphatidylcholines, phosphatidylinositol, phosphatidylserine, and bile acid metabolism products. Stratification of CHB1 and CHB2 patients by a simple logistic index, the PIPSindex, based on phosphatidylinositol (PI) and phosphatidylserine (PS), was achieved with an AUC of 0.961, which outperformed all currently available markers. A panel of serum metabolites that differentiate health control, CHB1 and CHB2 patients has been identified. The proposed metabolomic biosignature has the potential to be used as indicator for antiviral treatment for CHB management.<\/jats:p>","DOI":"10.1038\/srep30853","type":"journal-article","created":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T09:14:59Z","timestamp":1470647699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B"],"prefix":"10.1038","volume":"6","author":[{"given":"Haijun","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxi","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,8]]},"reference":[{"key":"BFsrep30853_CR1","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Trepo","year":"2014","unstructured":"Trepo, C., Chan, H. L. & Lok, A. Hepatitis B virus infection. Lancet. 384, 2053\u20132063 (2014).","journal-title":"Lancet."},{"key":"BFsrep30853_CR2","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1056\/NEJM200205303462202","volume":"346","author":"AS Lok","year":"2002","unstructured":"Lok, A. S. Chronic hepatitis B. N Engl J Med. 346, 1682\u20131683 (2002).","journal-title":"N Engl J Med."},{"key":"BFsrep30853_CR3","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw, Y. F. et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 351, 1521\u20131531 (2004).","journal-title":"N Engl J Med."},{"key":"BFsrep30853_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen, C. J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 295, 65\u201373 (2006).","journal-title":"JAMA."},{"key":"BFsrep30853_CR5","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1002\/hep.22898","volume":"49","author":"BJ McMahon","year":"2009","unstructured":"McMahon, B. J. The natural history of chronic hepatitis B virus infection. Hepatology. 49, S45\u2013S55 (2009).","journal-title":"Hepatology."},{"key":"BFsrep30853_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jhep.2014.10.026","volume":"62","author":"MF Yuen","year":"2015","unstructured":"Yuen, M. F. et al. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. J Hepatol. 62, 526\u2013532 (2015).","journal-title":"J Hepatol."},{"key":"BFsrep30853_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","volume":"2","author":"YF Liaw","year":"2008","unstructured":"Liaw, Y. F. et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2, 263\u2013283 (2008).","journal-title":"Hepatol Int."},{"key":"BFsrep30853_CR8","doi-asserted-by":"crossref","unstructured":"European Association For The Study Of The, L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 57, 167\u2013185 (2012).","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"BFsrep30853_CR9","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/j.jhep.2015.01.018","volume":"62","author":"S Locarnini","year":"2015","unstructured":"Locarnini, S., Hatzakis, A., Chen, D. S. & Lok, A. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. J Hepatol. 62, S76\u2013S86 (2015).","journal-title":"J Hepatol."},{"key":"BFsrep30853_CR10","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s10620-015-3982-4","volume":"61","author":"LA Uribe","year":"2015","unstructured":"Uribe, L. A. et al. Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation. Dig Dis Sci. 61, 618\u2013625 (2015).","journal-title":"Dig Dis Sci."},{"key":"BFsrep30853_CR11","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/hep.22518","volume":"48","author":"GV Papatheodoridis","year":"2008","unstructured":"Papatheodoridis, G. V. et al. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology. 48, 1451\u20131459 (2008).","journal-title":"Hepatology."},{"key":"BFsrep30853_CR12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1365-2893.2007.00957.x","volume":"15","author":"GV Papatheodoridis","year":"2008","unstructured":"Papatheodoridis, G. V., Chrysanthos, N., Hadziyannis, E., Cholongitas, E. & Manesis, E. K. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat. 15, 434\u2013441 (2008).","journal-title":"J Viral Hepat."},{"key":"BFsrep30853_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00430-014-0380-z","volume":"204","author":"X Zheng","year":"2015","unstructured":"Zheng, X., Wang, J. & Yang, D. Antiviral therapy for chronic hepatitis B in China. Med Microbiol Immunol. 204, 115\u2013120 (2015).","journal-title":"Med Microbiol Immunol."},{"key":"BFsrep30853_CR14","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/hep.22476","volume":"48","author":"MJ Tong","year":"2008","unstructured":"Tong, M. J., Hsien, C., Hsu, L., Sun, H. E. & Blatt, L. M. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology. 48, 1070\u20131078 (2008).","journal-title":"Hepatology."},{"key":"BFsrep30853_CR15","doi-asserted-by":"publisher","first-page":"e80585","DOI":"10.1371\/journal.pone.0080585","volume":"8","author":"H Wang","year":"2013","unstructured":"Wang, H. et al. Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. PLoS One. 8, e80585 (2013).","journal-title":"PLoS One."},{"issue":"4","key":"BFsrep30853_CR16","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1111\/jvh.12010","volume":"20","author":"H. Wang","year":"2012","unstructured":"Wang, H. et al. Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT. J Viral Hepat. 20, e3-10 (2013).","journal-title":"Journal of Viral Hepatitis"},{"key":"BFsrep30853_CR17","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jhep.2007.07.022","volume":"47","author":"M Lai","year":"2007","unstructured":"Lai, M., Hyatt, B. J., Nasser, I., Curry, M. & Afdhal, N. H. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 47, 760\u2013767 (2007).","journal-title":"J Hepatol."},{"key":"BFsrep30853_CR18","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/ajg.2009.248","volume":"104","author":"MH Nguyen","year":"2009","unstructured":"Nguyen, M. H. et al. Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels. Am J Gastroenterol. 104, 2206\u20132213 (2009).","journal-title":"Am J Gastroenterol."},{"key":"BFsrep30853_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0140-6736(86)90883-4","volume":"1","author":"B Maharaj","year":"1986","unstructured":"Maharaj, B. et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1, 523\u2013525 (1986).","journal-title":"Lancet."},{"key":"BFsrep30853_CR20","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","volume":"97","author":"A Regev","year":"2002","unstructured":"Regev, A. et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 97, 2614\u20132618 (2002).","journal-title":"Am J Gastroenterol."},{"key":"BFsrep30853_CR21","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1053\/j.gastro.2012.02.017","volume":"142","author":"L Castera","year":"2012","unstructured":"Castera, L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 142, 1293\u20131302 e1294 (2012).","journal-title":"Gastroenterology"},{"key":"BFsrep30853_CR22","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1111\/j.1572-0241.2006.00788.x","volume":"101","author":"M Mohamadnejad","year":"2006","unstructured":"Mohamadnejad, M. et al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol. 101, 2537\u20132545 (2006).","journal-title":"Am J Gastroenterol."},{"key":"BFsrep30853_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/jvh.12284","volume":"22","author":"JY Wang","year":"2015","unstructured":"Wang, J. Y. et al. Serum microRNA-124 is a novel biomarker for liver necroinflammation in patients with chronic hepatitis B virus infection. J Viral Hepat. 22, 128\u2013136 (2015).","journal-title":"J Viral Hepat."},{"key":"BFsrep30853_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.dld.2013.01.001","volume":"45","author":"HJ Huang","year":"2013","unstructured":"Huang, H. J. et al. Metabolomic analyses of faeces reveals malabsorption in cirrhotic patients. Dig Liver Dis. 45, 677\u2013682 (2013).","journal-title":"Dig Liver Dis."},{"key":"BFsrep30853_CR25","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jhep.2014.04.023","volume":"61","author":"M Cortes","year":"2014","unstructured":"Cortes, M. et al. Metabolomics discloses donor liver biomarkers associated with early allograft dysfunction. J Hepatol. 61, 564\u2013574 (2014).","journal-title":"J Hepatol."},{"key":"BFsrep30853_CR26","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1111\/liv.12541","volume":"34","author":"AI Fitian","year":"2014","unstructured":"Fitian, A. I. et al. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC\/MS and UPLC\/MS-MS. Liver Int. 34, 1428\u20131444 (2014).","journal-title":"Liver Int."},{"key":"BFsrep30853_CR27","doi-asserted-by":"crossref","unstructured":"Seijo, S. et al. Metabolomics as a diagnostic tool for idiopathic non-cirrhotic portal hypertension. Liver Int. doi: 10.1111\/liv.12972 (2015).","DOI":"10.1111\/liv.12972"},{"key":"BFsrep30853_CR28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1194\/jlr.M700184-JLR200","volume":"49","author":"MS Han","year":"2008","unstructured":"Han, M. S. et al. Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes. J Lipid Res. 49, 84\u201397 (2008).","journal-title":"J Lipid Res."},{"key":"BFsrep30853_CR29","doi-asserted-by":"publisher","first-page":"G77","DOI":"10.1152\/ajpgi.00301.2011","volume":"302","author":"K Kakisaka","year":"2012","unstructured":"Kakisaka, K. et al. Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol. 302, G77\u2013G84 (2012).","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"BFsrep30853_CR30","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1084\/jem.182.5.1597","volume":"182","author":"B Verhoven","year":"1995","unstructured":"Verhoven, B., Schlegel, R. A. & Williamson, P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J Exp Med. 182, 1597\u20131601 (1995).","journal-title":"J Exp Med."},{"key":"BFsrep30853_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1042\/bj3160531","volume":"316","author":"Y Lin","year":"1996","unstructured":"Lin, Y. et al. Characterization of the inhibitory effects of bile acids on very-low-density lipoprotein secretion by rat hepatocytes in primary culture. Biochem J. 316 (Pt. 2), 531\u2013538 (1996).","journal-title":"Biochem J."},{"key":"BFsrep30853_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0167-4889(91)90058-6","volume":"1091","author":"H Takikawa","year":"1991","unstructured":"Takikawa, H., Tomita, J., Takemura, T. & Yamanaka, M. Cytotoxic effect and uptake mechanism by isolated rat hepatocytes of lithocholate and its glucuronide and sulfate. Biochim Biophys Acta. 1091, 173\u2013178 (1991).","journal-title":"Biochim Biophys Acta."},{"key":"BFsrep30853_CR33","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1478-3231.2007.01475.x","volume":"27","author":"M Mari","year":"2007","unstructured":"Mari, M. & Fernandez-Checa, J. C. Sphingolipid signalling and liver diseases. Liver Int. 27, 440\u2013450 (2007).","journal-title":"Liver Int."},{"key":"BFsrep30853_CR34","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/jn\/119.4.534","volume":"119","author":"TO Messmer","year":"1989","unstructured":"Messmer, T. O., Wang, E., Stevens, V. L. & Merrill, A. H. Jr. Sphingolipid biosynthesis by rat liver cells: effects of serine, fatty acids and lipoproteins. J Nutr. 119, 534\u2013538 (1989).","journal-title":"J Nutr."},{"key":"BFsrep30853_CR35","doi-asserted-by":"crossref","unstructured":"Nagahashi, M. et al. DNA damage response and sphingolipid signaling in liver diseases. Surg Today. doi: 10.1007\/s00595-015-1270-8 (2015).","DOI":"10.1007\/s00595-015-1270-8"},{"key":"BFsrep30853_CR36","doi-asserted-by":"crossref","unstructured":"European Association For The Study Of The, L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 50, 227\u2013242 (2009).","DOI":"10.1016\/j.jhep.2008.10.001"},{"key":"BFsrep30853_CR37","unstructured":"Wold, S., Johansson, E. & Cocchi, M. In 3D QSAR in Drug Design; Theory, Methods and Applications. (ed Kubinyi, H. ) 523\u2013550 (ESCOM Science Publisher, 1993)."},{"key":"BFsrep30853_CR38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/cem.695","volume":"16","author":"J Trygg","year":"2002","unstructured":"Trygg, J. & Wold, S. Orthogonal Projections to Latent Structures (OPLS). Journal of Chemometrics. 16, 119\u2013128 (2002).","journal-title":"Journal of Chemometrics."},{"key":"BFsrep30853_CR39","doi-asserted-by":"publisher","first-page":"e1003123","DOI":"10.1371\/journal.pcbi.1003123","volume":"9","author":"S Li","year":"2013","unstructured":"Li, S. et al. Predicting network activity from high throughput metabolomics. PLoS Comput Biol. 9, e1003123 (2013).","journal-title":"PLoS Comput Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep30853.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep30853","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep30853.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T06:15:22Z","timestamp":1672899322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep30853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,8]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,8,26]]}},"alternative-id":["BFsrep30853"],"URL":"https:\/\/doi.org\/10.1038\/srep30853","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,8]]},"assertion":[{"value":"5 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30853"}}